Provided by Tiger Trade Technology Pte. Ltd.

CHINARES PHARMA

4.590
-0.060-1.29%
Volume:11.16M
Turnover:51.73M
Market Cap:28.84B
PE:6.11
High:4.710
Open:4.640
Low:4.590
Close:4.650
52wk High:6.336
52wk Low:4.211
Shares:6.28B
HK Float Shares:6.28B
Volume Ratio:1.15
T/O Rate:0.18%
Dividend:0.22
Dividend Rate:4.75%
EPS(LYR):0.751
ROE:8.32%
ROA:2.64%
PB:0.47
PE(LYR):6.11
PS:0.09

Loading ...

Dong-E-E-Jiao, China Resources Pharma Subsidiary, Posts H1 Net Profit RMB 860.38 Million, up 5.66%

Reuters
·
Aug 20

CHINARES PHARMA Sets 24 Aug 2026 Board Meeting to Approve 1H26 Results and Possible Interim Dividend

Bulletin Express
·
Aug 12

China Resources Pharma to Review Interim Results, Weigh Dividend at Board Meeting

Reuters
·
Aug 12

CHINARES PHARMA Affirms 6.28 Billion Outstanding Shares and Adequate Public Float in July 2026 Return

Bulletin Express
·
Aug 03

China Resources Pharmaceutical Group - Unit to Buy 23.50% of Lier Chemical

THOMSON REUTERS
·
Jul 30

China Resources Pharmaceutical Group - Deal Valued at Rmb5,656.25 Mln or Rmb30.07 Per Share

THOMSON REUTERS
·
Jul 30

China Resources Pharma Unit Sells 1 Billion Yuan Bonds

MT Newswires Live
·
Jul 22

CR Pharma completes RMB 1.00 billion first-tranche medium-term note issue at 1.53% coupon

Bulletin Express
·
Jul 22

CHINARES PHARMA Successfully Issues Inaugural Medium-Term Note Series

Stock News
·
Jul 22

China Resources Pharmaceutical’s CR Double-Crane Emerges Top Bidder for 23.50% Stake in Lier Chemical

Bulletin Express
·
Jul 15

China Resources Pharmaceutical Group - Cr Double-crane Ranks First in Bid for Lier Chemical Stake on July 15, 2026

THOMSON REUTERS
·
Jul 15

China Resources Pharmaceutical Group - Unit Bids for 23.5% Stake in Lier Chemical

THOMSON REUTERS
·
Jul 15

China Resources Pharma Unit Tops Bid to Buy 23.5% Stake in Lier Chemical

Reuters
·
Jul 15

CR Sanjiu's Profit Slips 7.9% in H1

MT Newswires Live
·
Jul 14

Tasly Pharmaceutical Reports H1 2026 Net Profit Attributable to Shareholders of RMB893 Million, Up 15.23%

Stock News
·
Jul 14

CHINARES PHARMA’s Subsidiary Tasly Pharmaceutical Delivers 15% Net-Profit Growth in 1H26 on Improved Margins Despite Softer Sales

Bulletin Express
·
Jul 14

CR Pharma Subsidiary KPC Warns of RMB330-400 Million H1 2026 Loss on Policy and Market Headwinds

Bulletin Express
·
Jul 14

China Resources Pharma Unit KPC Expects H1 Net Loss of RMB 400 Million to RMB 330 Million

Reuters
·
Jul 14

CHINARES PHARMA Announces Board Changes: Guo Chuan Resigns, Zhang Jing Joins as Non-Executive Director

Bulletin Express
·
Jul 13

China Resources Pharma Announces Board Changes: Zhang Jing Appointed as Non-Executive Director

Stock News
·
Jul 13